Paxlovid No Longer Prevents COVID Hospitalization in Vaccinated Adults Studies Find
Two major trials show Paxlovid doesn't reduce hospitalization or death in vaccinated COVID patients, though it may speed recovery.
Summary
Two large clinical trials — the UK-based PANORAMIC and Canada's CanTreatCOVID — found that Paxlovid (nirmatrelvir-ritonavir) did not significantly reduce hospitalization or death in COVID-19 patients who were already vaccinated. Published in the New England Journal of Medicine, the studies reflect a changed pandemic landscape where most adults carry prior immunity. Hospitalization and death rates were already very low in both groups, hovering below 1.2%, making it difficult for the drug to show added benefit. However, Paxlovid was linked to faster recovery and lower viral loads by day 5 when taken early. Experts including Fauci and Lane note the drug's original 89% risk reduction data came from unvaccinated populations and no longer applies broadly today.
Detailed Summary
Two rigorous multicenter clinical trials have challenged the routine use of Paxlovid for COVID-19 in today's largely vaccinated population, raising important questions for health-conscious individuals and clinicians about when — and whether — the antiviral is still warranted.
The PANORAMIC trial in the UK and the CanTreatCOVID trial in Canada both found that adding Paxlovid to usual care did not significantly reduce all-cause hospitalization or death within 28 days. In PANORAMIC, hospitalization or death occurred in 0.8% of Paxlovid recipients versus 0.7% with usual care alone. In CanTreatCOVID, rates were 0.6% versus 1.2% — a numerical difference that still failed to reach statistical significance. Neither trial met the pre-specified 97.5% probability threshold for superiority.
Published together in the New England Journal of Medicine, the findings were accompanied by an editorial from former NIAID leaders Anthony Fauci and H. Clifford Lane. They emphasized that Paxlovid's original approval was based on the EPIC-HR trial involving unvaccinated adults, where it showed an 89% relative risk reduction. That context no longer reflects most patients today, who carry varying degrees of immunity from vaccination or prior infection.
Despite the null findings on hard outcomes, Paxlovid was associated with faster sustained recovery and greater likelihood of undetectable viral load by day 5 when taken within the first five days of illness. These secondary benefits may still matter for high-risk individuals or those seeking to minimize symptom duration.
The practical implication is nuanced: Paxlovid is unlikely to prevent death or hospitalization in vaccinated, lower-risk adults but may still offer recovery benefits. Clinicians and patients should weigh individual risk profiles, vaccination status, and current variant landscape before defaulting to treatment. Blanket prescribing in vaccinated populations appears no longer evidence-supported.
Key Findings
- Paxlovid did not significantly reduce hospitalization or death in vaccinated COVID patients in two major trials.
- Original 89% risk reduction data came from unvaccinated populations and does not apply to current conditions.
- Paxlovid was linked to faster recovery and lower viral loads at day 5 when taken within 5 days of symptom onset.
- Hospitalization and death rates were already below 1.2% in both trial arms, limiting room for drug benefit.
- Experts say Paxlovid may still have a role for high-risk individuals despite null results on hard outcomes.
Methodology
This is a news report summarizing two peer-reviewed randomized clinical trials published in the New England Journal of Medicine, a top-tier medical journal. The PANORAMIC trial enrolled over 3,000 higher-risk participants; CanTreatCOVID was smaller but similarly designed. Both used Bayesian statistical frameworks with pre-specified superiority thresholds.
Study Limitations
The article is a news summary and does not provide full trial data; readers should consult the original NEJM publications for complete methodology and subgroup analyses. Both trials were conducted in community settings and may not reflect outcomes in severely immunocompromised populations. Variant-specific effects and long COVID outcomes were not addressed in this report.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.